Log In
Print
BCIQ
Print
Print this Print this
 

Subcutaneous Cinryze

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionComplement 1 (C1) esterase inhibitor
Molecular Target Complement 1 (C1) esterase
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationAngioedema
Indication DetailsPrevent attacks of hereditary angioedema (HAE); Treat attacks of hereditary angioedema (HAE)
Regulatory Designation

Partner

Halozyme Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today